Patients with non-seasonal depression who were treated with bright light therapy reported a 40% remission rate, according to a recent study.

The projected winner: The drug that produces the best outcome at six months in the battle against depression ... more ...

Schizoaffective disorder is a chronic mental health condition characterized by symptoms of both schizophrenia and mood disorders, such as bipolar disorder or major depression. This dual nature of the ...

agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder ...

Mirtazapine is an FDA- approved, prescription-only medication for major depressive disorder in adults. The medication works by increasing certain hormones in the brain to improve mood. Whichever ...

A recent retrospective, cross-sectional study found that detecting self-injurious thoughts and behaviors in youth requires ...

Supernus (SUPN) announced data in a poster presentation at Psych Congress 2024 with new data from its exploratory open-label Phase 2a clinical ...

New research reveals that perimenopausal women are more than twice as likely to develop bipolar disorder for the first time.

AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

These “interventions” are usually delivered with an air of expert kindness, that is often patronizing. Almost all of my ...

The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT ... IW is uniquely ...

According to the National Institute of Mental Health one in five United States adults live with mental illness. PermiaCare is a west Texas non-profit that’s helping ...